Resolian

  1. Home

  2. caret-right icon

    Immunoassay Solutions

  3. caret-right icon

    About Gyrolab

  4. caret-right icon

    CRO Partners

  5. caret-right icon

    Resolian

“With a team of dedicated technical specialists, 16 trained analysts and three 5-CD Gyrolab instruments, we have the knowledge and capacity to develop, transfer and validate bespoke methods whilst supporting large sample analysis studies in parallel”

Resolian Bioanalytics UK have used Gyrolab technology for over 15 years, acquiring their first instrument in 2007 and becoming the first CRO to establish a GLP-validated method on the platform. Their Gyrolab capabilities have grown since and they now utilize their 3 validated Gyrolab instruments to support multiple late and early-phase clinical studies, pre-clinical GLP studies, and exploratory drug discovery studies. Although the main application remains pharmacokinetic (PK) and pharmacodynamic (PD) studies, analyzing a range of matrices including plasma, serum, CSF, and tissue homogenates, the bioanalytical team have also utilized the ADA mixing CD application and are also investigating the use of Gyrolab for oligonucleotide quantification, which is of increasing interest for their sponsors.

Resolian logo-green

Advocating Gyrolab Technology

Richard Hughes, Scientific Director at Resolian has advocated the use of Gyrolab technology for many years. He explains: “Replacing periods of passive binding with short incubations and nanofluidics changes the paradigm of how the assays are working. Assays that don't work in a standard format can work in Gyrolab system, which has helped in several cases where ELISA has failed. Using the Gyrolab system can lead to a step change in performance and gives levels of assay robustness not seen on plate-based methods.” He continues, "With a team of dedicated technical specialists, 16 trained analysts and three 5-CD Gyrolab instruments, we have the knowledge and capacity to develop, transfer and validate bespoke methods whilst supporting large sample analysis studies in parallel". 

With a team of dedicated technical specialists and analytical project managers, Resolian Bioanalytics prides itself on being able to offer customers high levels of technical expertise, commitment, and responsiveness. They are regular contributors to the annual Gyrolab User Group and have a wealth of knowledge in the development and validation of bioanalytical methods to ICH M10 guidelines. 

Resolian Provides Integrated Bioanalytical Support

As one of Europe’s largest dedicated bioanalytical centers, we are industry leaders in providing integrated bioanalytical support across all phases of drug development. Our large and flexible capacity allows us to allocate resources to match the customer’s needs, from method development projects to large, complex multi-center clinical trials. Our capabilities include:

  • Bioanalytical method development and validation in adherence to the latest industry guidance.
  • Analysis of samples in support of all phases of drug development in compliance with the regulatory requirements for GLP and GCP.
  • Services include PK, PD, immunogenicity, flow cytometry and cell-based assays which can be supported by in-house data management, statistical analysis and kits and logistics teams.  

Contributions to the Bioanalytical Community

Resolian regularly contributes to the bioanalytical community, presenting at the annual Gyrolab User Group Conference, EBF, Reid and Biomarkers UK. Recent podium presentations include:

  1. “Strategies to overcome selectivity issues in LBA PK assays using the Gyrolab”, Tom Wilford, Reid 2023
  2. “Strategies for measuring Oligonucleotides using Gyrolab”, Issa Jyamubandi, Reid 2023
  3. “Microsampling on the Gyrolab”, Richard Hughes, Gyros User Group Conference 2023
  4. “Talking Non-Sense: Measuring High Analyte Concentrations using Biotinylated Non-sense protein”, Annabel Hood, Gyros User Group Conference 2023
  5. “Problems and Solutions in the pursuit of perfect parallelism”, Tom Wilford, Biomarkers UK 2023
  6. “ADA method to detect antibodies against transgene: Alpha-Galactosidase as a case study”, Issa Jyamubandi, Gyros User Group Conference 2022


To find out more, visit Resolian's website or contact BD@resolian.com.